Champiat, S., Kuttschreuter, L., Chawla, N. S., Carter, L., Kao, S. C., Woodcock, V. K., Benafif, S., Evans, T. J., Humphries, T. G., Walter, H. S., Karabajakian, A., Grimaldi, A., Hoffmann, C., Pierce, A., Sankhala, K. K. (2026). Updated design of INVOKE: A phase 1 study of OKN4395, a first-in-class EP2/EP4/DP1 triple prostanoid receptor antagonist, in patients with advanced solid tumors.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.tps2681